Engineered bacterial vesicle platform for scalable bioactive production
BioClé has developed a bacterial extracellular vesicle (bEV) platform using engineered GRAS microorganisms for scalable production and delivery of functional biomolecules. This innovative approach offers improved stability, bioavailability, and manufacturing efficiency.
Overview
BioClé's engineered bacterial extracellular vesicle (bEV) platform revolutionizes the production and delivery of functional biomolecules. By utilizing engineered GRAS microorganisms, this platform enables the scalable production of bioactives, metabolites, peptides, and other compounds. The technology is designed to reduce formulation complexity while enhancing stability and bioavailability. The use of low-cost and waste-derived feedstocks ensures that the platform is not only efficient but also aligns with sustainable production practices. This approach is ideal for consumer-packaged goods, offering a more sustainable alternative to traditional ingredient production methods.
Technical specifications
Key features:
- Utilizes synthetic biology and microbial fermentation to produce natural bio-derived nanostructures.
- Modular platform capable of integrating with industrial manufacturing processes.
- Compatible with low-cost and potentially waste-derived feedstocks.
- Scalable downstream processing for efficient production.
The platform leverages the natural molecular transport mechanisms of bacteria, providing a programmable system for the production and delivery of biomolecules. This innovative approach integrates strain engineering, defined media, and optimized fermentation workflows to achieve high yields and efficient production economics.
Technology readiness level
The bEV platform is currently at Technology Readiness Level 4, with ongoing development focused on improving yield, scalability, and production economics. BioClé is actively validating the platform with functional bioactive payloads and exploring alternative feedstocks. Continued collaboration with industrial partners will drive further advancements and commercial readiness.
About BioClé
BioClé is a biotechnology startup that has developed an intelligent delivery platform based on bacterial extracellular vesicles (bEVs). The technology is designed to enhance the stability, bioavailability, and targeted cellular uptake of bioactive compounds, which often lose efficacy due to degradation during digestion. By utilizing modified bacteria to produce these vesicles at scale, the company aims to solve significant challenges in the delivery of ingredients such as butyrate, allowing them to reach intestinal cells intact and active. The company employs synthetic biology and biological nanotechnology to create a delivery system that functions as a natural vehicle for health and nutritional applications.
Operating with a B2B business model, BioClé intends to partner with laboratories, nutraceutical companies, and food manufacturers by providing them with a technology platform to improve the performance of their functional products. By addressing the limitations of traditional delivery methods like capsules or liposomes, the company seeks to enable next-generation gut health solutions. Based in Rosario, Argentina, with an international outlook, BioClé was incubated at the Institute of Molecular and Cellular Biology of Rosario (IBR) and is supported by investment firms including GRIDX. The company is actively validating its platform through both in vitro and in vivo studies to support commercial adoption.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.